International perspectives on genetic counseling and testing for breast cancer risk

Breast Disease

Volumn 27, Issue 1, 2007, Pages 109-125

  Meiser, Bettina ^a   Gaff, Clara ^b,c   Julian Reyniere, Claire ^d   Biesecker, Barbara B ^e   Esplene, Mary Jane ^f   Vodermaier, Andrea ^f,g   Tibben, Aaad ^h  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Genetic Health Services Victoria   (Australia)

^d INSERM   (France)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY OF MUNICH   (Germany)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Genetic counseling; Genetic testing; Hereditary breast cancer; International differences

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENOMIC DNA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CULTURAL FACTOR; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE AVAILABILITY; HEALTH SERVICE; HUMAN; PATIENT ATTITUDE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; RISK ASSESSMENT;

EID: 35048824744     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2007-27107     Document Type: Article

References (130)

1. R. Acton, N. Burst, L. Casebeer, S. Ferguson, P. Greene, B. Laird and L. Leviton, Knowledge, Attitudes and behaviors of Alabama's primary care providers regarding cancer genetics, Acad Med 75 (2000), 850-852.
2. K. Aktan-Collan, A. Haukkala and H. Kaariainen, Life and health insurance behaviour of individuals having undergone a predictive genetic testing programme for hereditary nonpolyposis colorectal cancer, Community Genetics 4 (2001), 219-224.
3. L. Andrews, B. Meiser, C. Apicella and K. Tucker, Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: A prospective study, Genet Test 8 (2004), 240-247.
4. Y. Antill, J. Reynolds, M. Young, K. Tucker, T. Bogtstra, S. Wong, T. Dudding, J. Di JUlio and K. Phillips, Risk-reduing surgery in women with familial susceptibility for breast and/or ovarian cancer, Eur J Cancer 42 (2006), 621-628.
5. K. Armstrong, K. Calzone, J. Stopfer, G. Fitzgerald, J. Coyne and B. Weeber, Factors assciated with decisions about clinical BRCA1/2 testing, Cancer Epidemiol Biomarkers Prev 9 (2000), 1251-1254.
6. K. Armstrong, E. Micco, A. Carney, J. Stopfer, M. Putt, K. Armstrong, E. Micco, A. Carney, J. Stopfer and M. Putt, Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer, see comment, JAMA 293 (2005), 1729-1736.
7. K. Armstrong, B. Weber, J. Stopfer, K. Calzone, M. Putt, J. Coyne and S. Schwart, Early use of clinical BRCA1/2 testing: Associations with race and breast cancer risk, American Journal of Medical Genetics 117A (2003), 154-160.
8. B. Arver, A. Haegermark, U. Platten, A. Lindblom and Y. Brandberg, Evaluation of psychosocial effects of presymptomatic testing for breast/ ovarian and colon cancer predisposing genes: A 12 month follow-up, Familial Cancer 3 (2004), 109-116.
9. Australian Cancer Network, Guidelines on familial aspects of cancer Sydney: Australian Cancer Network, November 1999.
10. B. Biesecker, N. Ishibe, D. Hadley, T. Giambarresi, R. Kase, C. Lerman and J. Struewing, Psychosocial factors predicting BRCA1/2 testing decisions in members of hereditary breast and ovarian cancer families, American Journal of Medical Genetics 93 (2000), 257-263.
11. B. Biesecker and T.M. Marteau, The future of genetic counselling: An international perspective, Nat Genet 22 (1999), 133-137.
12. A. Bish, S. Sutton, C. Jacobs, S. Levene, A. Ramirez and S. Hodgson, No news is (not necessarily) good news: Impact of preliminary results for BRCA1 mutation searches, Genet Med 4 (2002), 353-358.
13. E.M.A. Bleiker, N.K. Aaronson and F.H. Menko, Genetic counseling for hereditary cancer: A pilot study on experiences of patients and family members, Patient Educ Couns 32 (1997), 107-116.
14. V. Bonadona, P. Saltel, F. Desseigne, H. Mignotte, J.C. Saurin, Q. Wang, O. Sinilnikova, S. Giraud, G. Freyer, H. Plauchu, A. Puisieux, C. Lasset, V. Bonadona, P. Saltel, F. Desseigne, H. Mignotte, J.-C. Saurin, Q. Wang, O. Sinilnikova, S. Giraud, G. Freyer, H. Plauchu, A. Puisieux and C. Lasset, Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: Reactions and behavior after the disclosure of a positive test result, Cancer Epidemiology, Biomarkers & Prevention 11 (2002), 97-104.
15. J. Botkin, K. Smith, R. Croyle, B. Baty, J. Wylie, D. Dutson, A. Chan, H. Hamann, C. Lerman, J. McDonald, V. Venne, J. Ward and E. Lyon, Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing, American Journal of Medical Genetics 118A (2003), 201-209.
16. L. Bouchard, I. Blancquaert, F. Eisinger, W.D. Foulkes, G. Evans, H. Sobol and C. Julian-Reynier, Prevention and genetic testing for breast cancer: Variations in medical decisions, Soc Sci Med 58 (2004), 1085-1096.
17. K. Brain, J. Gray, P. Norman, E. Parsons, A. Clarke, C. Rogers, R. Mansel, P. Harper, K. Brain, J. Gray, P. Norman, E. Parsons, A. Clarke, C. Rogers, R. Mansel and P. Harper, Why do women attend familial breast cancer clinics? see comment, J Med Genet 37 (2000), 197-202.
18. M. Broadstock, S. Michie, J. Gray, J. MacKay and T.M. Marteau, The psychological consequences of offering mutation searching in the family for those at risk of hereditary breast and ovarian cancer - A pilot study, Psychooncology 9 (2000), 537-548.
19. L. Brooks, F. Lennard, A. Shenton, F. Lalloo, I. Ambus, A. Ardern-Jones, R. Belk, B. Kerr, D. Craufurd, R. Eeles and G. Evans, BRCA1/2 predictive testing: A study of uptake in two centres, Eur J Hum Genet 12 (2004), 654-662.
20. Bundesärtzekammer, Richtlinien zur Diagnose der genetischen Disposition für Krebserkrankungen (German guidelines for the diagnosis of genetic disposition for cancer) Deutsches Ärtzteblatt 95 (1998).
21. M. Cappelli, L. Surh, L. Humphreys, S. Verma, D. Logan, A. Hunter, J. Allanson, M. Cappelli, L. Surh, L. Humphreys, S. Verma, D. Logan, A. Hunter and J. Allanson, Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer, Clin Genet 55 (1999), 419-430.
22. T. Caulfield, Policy conflicts: Gene patents and health care in Canada, Community Genetics 8 (2005), 223-227.
23. C. Charles, A. Gafini and T. Whelan, Shared decision-making in the medical encounter: What does it matter? Soc Sci Med 44 (1997), 681-692.
24. E. Claes, G. Evers-Kiebooms, L. Denayer, M. Decruyenaere, A. Boogaerts, K. Philippe and E. Legius, Predictive genetic testing for hereditary breast and ovarian cancer: Psychological distress and illness representations 1 year following disclosure, J Genet Couns 14 (2005), 349-363.
25. R.T. Croyle, K.R. Smith, J.R. Botkin, B. Baty and J. Nash, Psychological responses to BRCA1 mutation testing: Preliminary findings, Health Psychol 16 (1997), 63-72.
26. Department of Health, The genetics of common diseases: A second report to the NHS Central Research and Development Committee on the new genetics, Leeds: 1995,
27. M. Dorval, A.F. Patenaude, K.A. Schneider, S.A. Kieffer, L. DiGianni, K.J. Kalkbrenner, J.I. Bromberg, L.A. Basili, K. Calzone, J. Stopfer, B.L. Weber, J.E. Garber, M. Dorval, A.F. Patenaude, K.A. Schneider, S.A. Kieffer, L. DiGianni, K.J. Kalkbrenner, J.I. Bromberg, L.A. Basili, K. Calzone, J. Stopfer, B.L. Weber and J.E. Garber, Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: Findings from p53 and BRCA1 testing programs, J Clin Oncol 18 (2000), 2135-2142.
28. F. Eisinger, N. Alby, A. Bremond, J. Dauplat, M. Espie, P. Janiaud, F. Kuttenn, J.P. Lebrun, J.B. Lefranc, J. Pierret, H. Sobol, D. Stoppa-Lyonnet, D. Thouvenin, H. Tristant and J. Feingold, Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee, Ann Oncol 9 (1998), 939-950.
29. F. Eisinger, B. Bressac, D. Castaigne, P.H. Cottu, J. Lansac, J.P. Lefranc, A. Lesur, C. Nogues, J. Pierret, S. Puy-Pernias, H. Sobol, A. Tardivon, H. Tristant, R. Villet, F. Eisinger, B. Bressac, D. Castaigne, P.-H. Cottu, J. Lansac, J.-P. Lefranc, A. Lesur, C. Nogues, J. Pierret, S. Puy-Pernias, H. Sobol, A. Tardivon, H. Tristant and R. Villet, Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004), see comment, Bull Cancer (Paris) 91 (2004), 219-237.
30. F. Eisinger, G.B. Geller, W and N. Holtzman, Cultural basis for differences between US and French clinical recommendations for women at increased risk for breast and ovarian cancer, Lancet 353 (1999), 919-920.
31. M. Esplen, L. Madlensky, K. Butler, W. McKinnon, B. Bapat, J. Wong, M. Aronson and S. Gallinger, Motivations and psychosocial impact of genetic testing for HNPCC, American Journal of Medical Genetics 103 (2001), 9-15.
32. C. Foster, D. Evans, R. Eeles, D. Eccles, S. Ashley, L. Brooke, R. Davidson, J. Mackay, P. Morrison and M. Watson, Predictive testing for BRCA1/2: Attributes, risk perception and management in a multi-centre clinical cohort, Br J Cancer 86 (2002), 1209-1216.
33. C. Foster, D.G. Evans, R. Eeles, D. Eccles, S. Ashley, L. Brooks, T. Cole, J. Cook, R. Davidson, H. Gregory, J. Mackay, P.J. Morrison and M. Watson, Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: Attributes, cancer worry, and barriers to testing in a multicenter clinical cohort, Genet Test 8 (2004), 23-29.
34. A.N. Freedman, L. Wideroff, L. Olson, W, Davis, C. Klabunde, K.P. Srinath, B.B. Reeve, R.T. Croyle and R. Ballard-Barbash, US physicians' attitudes toward genetic testing for cacer susceptibility, American Journal of Medical Genetics 120A (2003), 63-71.
35. L. Friedman, J. Webb, S. Richards, G. Lynch, A. Kaplan, F. Brunicardi and S. Plon, Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim, Genet Med 1 (1999), 74-79.
36. A. Geirdal, J.G. Reichelt, A.A. Dahl, K. Heimdl, L. Maehle, A. Stormorken and P. Moller, Psychological distress in women at risk of hereditary breast/ovarian or HSPCC cancers in the absence of demonstrated mutations, Familial Cancer 4 (2005), 121-126.
37. N. Hallowell, C. Foster, A. Ardern-Jones, R. Eeles, V. Murday and M. Watson, Genetic testing for women previously diagnosed with breast/ ovarian cancer: Examining the impact of BRCA1 and BRCA2 mutation searching, Genet Test 6 (2002), 79-87.
38. N. Hallowell, C. Foster, R. Eeles, A. Arden-Jones and M. Watson, Accommodating risk: Responses to BRCA1/2 genetic testing of women who have had cancer, Soc Sci Med 59 (2004), 553-565.
39. N. Hallowell, F. Murton, H. Statham, J.M. Green and M.P.M. Richards, Women's need for information before attending genetic counselling for familial breast or ovarian cancer: A questionnaire, interview and observational study, Br Med J 314 (1997), 281-283.
40. M. Hannemann, R. Fox and M. James, Ovarian cancer death reduction for women at high risk: Workload implications for gynaecology services, Journal of Obstetrics & Gynaecology 26 (2006), 42-44.
41. L. Hartmann, T. Sellers, D. Schaid, T. Frank, C. Soderberg, D. Sitta, M. Frost, C. Grant, J. Donohue and J. Woods, Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers, J Natl Cancer Inst 93 (2001), 1633-1637.
42. L.C. Hartmann, D.J. Schaid, J.E. Woods, T.P. Crotty, J.L. Myers, P.G. Arnold, P.M. Petty, T.A. Sellers, J.L. Johnson, S.K. McDonnel, M.H. Frost and R.B. Jenkins, Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med 340 (1999), 77-84.
43. S. Ho, J. Ho, C. Chan, K. Kwan and Y. Tsui, Decisional consideration of hereditary colon cancer genetic test results among Hong Kong Chinese adults, Cancer Epidemiol Biomarkers Prev 12 (2003), 426-432.
44. S. Hodgson, B. Milner, I. Brown, G. Bevilacqua, J. Chang-Claude, D. Eccles, G. Evans, H. Gregory, P. Moller, P. Morrison, M. Steel, D. Stoppa-Lyonett, H. Vasen and N. Haites, Cancer genetics services in Europe, Dis Markers 15 (1999), 3-13.
45. P. Hopwood, C.J. van Asperen, G. Borreani, P. Bourret, M. Decruyenaere, S. Dishon, F. Eisinger, D.G. Evans, G. Evers-Kiebooms, L. Gangeri, L. Hagoel, E. Legius, I. Nippert, G. Rennert, B. Schlegelberger, C. Sevilla, H. Sobol, A. Tibben, M. Welkenhuysen, C. Julian-Reynier, P. Hopwood, C.J. van Asperen, G. Borreani, P. Bourret, M. Decruyenaere, S. Dishon, F. Eisinger, D.G.R. Evans, G. Evers-Kiebooms, L. Gangeri, L. Hagoel, E. Legius, I. Nippert, G. Rennert, B. Schlegelberger, C. Sevilla, H. Sobol, A. Tibben, M. Welkenhuysen and C. Julian-Reynier, Cancer genetics service provision: A comparison of seven European centres, Community Genetics 6 (2003), 192-205.
46. C. Hughes, G.A. Fasaye, V.H. LaSalle and C. Finch, Sociocultural influences on participation in genetic risk assessment and testing among African American women, Patient Education & Counseling 51 (2003), 107-114.
47. C. Hughes, A. Gomez-Caminero, J. Benkendorf, J. Kerner, C. Isaacs, J. Barter and C. Lerman, Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk, Patient Educ Couns 32 (1997), 51-62.
48. P.B. Jacobsen, H.B. Valdimarsdottir, K.L. Brown and K. Offit, Decision-making about genetic testing among women at familial risk for breast cancer, Psychosom Med 59 (1997), 459-466.
49. C. Julian-Reynier, F. Eisinger and F. Chabal, Cancer genetics clinics: Target populations and consultees' expectations, Eur J Cancer 32A (1996), 398-403.
50. C. Julian-Reynier, F. Eisinger, J. Moatti and H. Sobol, Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines, Eur J Hum Genet 8 (2000), 204-208.
51. C.M. Julian-Reynier, L.J. Bouchard, D.G. Evans, F.A. Eisinger, W.D. Foulkes, B. Kerr, I.R. Blancquaert, J.P. Moatti, H.H. Sobol, C.M. Julian-Reynier, L.J. Bouchard, D.G. Evans, F.A. Eisinger, W.D. Foulkes, B. Kerr, I.R. Blancquaert, J.P. Moatti and H.H. Sobol, Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: Differences among English, French, and Canadian women, Cancer 92 (2001), 959-968.
52. E. Julian-Reynier, F. Chabal, Y. Aurran, Y.J. Bignon, C. Nogues, M. Machelard, C. Maugard, P. Vennin and H. Sobol, Cancer genetic clinics: Why do women who already have had cancer attend? Eur J Cancer 34 (1998), 1549-1553.
53. J. Julian-Reynier, H. Sobol, C. Sevilla, C. Nogues, P. Bourret and the French Cancer Genetic Network, Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families, Psychooncology 9 (2000), 504-510.
54. N.D. Kauff, J.M. Satagopan, M.E. Robson, L. Scheuer, M. Hensley, C.A. Hudis, N.A. Ellis, J. Boyd, P.I. Borgen, R.R. Barakat, L. Norton, M. Castiel, K. Nafa, K. Offit, N.D. Kauff, J.M. Satagopan, M.E. Robson, L. Scheuer, M. Hensley, C.A. Hudis, N.A. Ellis, J. Boyd, P.I. Borgen, R.R. Barakat, L. Norton, M. Castiel, K. Nafa and K. Offit, Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation, see comment, N Engl J Med 346 (2002), 1609-1615.
55. L.A. Keogh, M.C. Southey, J. Maskiell, M.A. Young, C.L. Gaff, J. Kirk, K.M. Tucker, D. Rosenthal, M.R. McCredie, G.G. Giles, J.L. Hopper, L.A. Keogh, M.C. Southey, J. Maskiell, M.-A. Young, C.L. Gaff, J. Kirk, K.M. Tucker, D. Rosenthal, M.R.E. McCredie, G.G. Giles and J.L. Hopper, Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study, Cancer Epidemiology, Biomarkers & Prevention 13 (2004), 2258-2263.
56. A. Kinney, L. Bloor, D. Mandal, S. Simonsen, B. Baty, R. Holubkov, K. Seggar, S. Neuhausen and K. Smith, The impact of receiving genetic test results on general and cancer-specific psychological distress among members of an African-American kindred with a BRCA1 mutation, Cancer 104 (2005), 2508-2516.
57. J.O.D. Klemp, A. Chamberlain and C. Fabian, CJ, Patient Satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial, Familial Cancer 4 (2005), 279-284.
58. J. Klijn, N. Janin, H. Cortes-Funes and R. Colomer, Should prophylactic surgery be used in women with a high risk of breast cancer? , Eur J Cancer Prev 33 (1997), 2149-2159.
59. S. Lee, B. Bernhardt and K. Helzsouer, Utilization of BRCA1/2 genetic testing in the clinical setting, Cancer 94 (2002), 1876-1885.
60. C. Lerman, B. Biesecker and J.L. Benkendorf, Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing., J Natl Cancer Inst 89 (1997), 148-157.
61. C. Lerman, M. Daly, A. Masny and A. Balshem, Attitudes about genetic testing for breast-ovarian cancer susceptibility, J Clin Oncol 12 (1994), 843-850.
62. C. Lerman, C. Hughes, R.T. Croyle, D. Main, C. Durham, C. Snyder, A. Bonney, J.F. Lynch, S.A. Narod, H.T. Lynch, C. Lerman, C. Hughes, R.T. Croyle, D. Main, C. Durham, C. Snyder, A. Bonney, J.F. Lynch, S.A. Narod and H.T. Lynch, Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing, Prev Med 31 (2000), 75-80.
63. C. Lerman, C. Hughes, S.J. Lemon, D. Main, C. Snyder, C. Durham, S. Narod, H.T. Lynch, C. Lerman, C. Hughes, S.J. Lemon, D. Main, C. Snyder, C. Durham, S. Narod and H.T. Lynch, What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing, see comment, J Clin Oncol 16 (1998), 1650-1654.
64. C. Lerman, S. Narod, K. Schulman, C. Hughes, A. Gomez-Caminero, G. Bonney, K. Gold, B. Trock, D. Main, J. Lynch, C. Fulmore, C. Snyder, S.J. Lemon, T. Conway, P. Tonin, G. Lenoir and H. Lynch, BRCA1 testing in families with hereditary breast-ovarian cancer, Journal of the American Medical Association 275 (1996), 1885-1892.
65. C. Lerman, J. Seay, A. Balshem and J. Audrain, Interest in genetic testing among first-degree relatives of breast cancer patients, American Journal of Medical Genetics 57 (1995), 385-392.
66. J. Lim, M. Macluran, M. Price, B. Bennett, P. Butow and kConFab Psychosocial Group, Short- and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer, Journal of Genetic Counseling 13 (2004), 115-133.
67. S. Loader, C.G. Shields and P.T. Rowley, Impact of genetic testing for breast-ovarian cancer susceptibility, Genet Test 8 (2004), 1-12.
68. E. Lobb, P. Butow, B. Meiser, K. Tucker and A. Barratt, How do geneticists and genetic counselors counsel women from high-risk breast cancer families? Journal of Genetic Counseling 10 (2001), 185-199.
69. L. Lodder, P.G. Frets, R.W. Trijsburg, E.J. Meijers-Heijboer, J.G. Klijn, H.J. Duivenvoorden, A. Tibben, A. Wagner, C.A. van der Meer, A.M. van den Ouweland, M.F. Niermeijer, L. Lodder, P.G. Frets, R.W. Trijsburg, E.J. Meijers-Heijboer, J.G. Klijn, H.J. Duivenvoorden, A. Tibben, A. Wagner, C.A. van der Meer, A.M. van den Ouweland and M.F. Niermeijer, Psychological impact of receiving a BRCA1/BRCA2 test result, American Journal of Medical Genetics 98 (2001), 15-24.
70. L. Lodder, P.G. Frets, R.W. Trijsburg, E.J. Meijers-Heijboer, J.G.M. Klijn, C. Seynaeve, A. van Geel, M. Tilanus, C. Bartles, L. Verhoog, C. Brekelmans, C. Burger and M. Niermeyer, One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: Emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery), Breast Cancer Res Treat 73 (2002), 97-112.
71. L. Lodder, P.G. Frets, R.W. Trijsburg, J.G.M. Klijn, C. Seynaeve, C., M.A.M. Tilanus, C.C.M. Bartels, E.J. Meijers-Heijboer, L.C. Verhoog and M.F. Niermeijer, Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing, American Journal of Medical Genetics 119A (2003), 266-272.
72. A.M. Lucassen and R.S. Houlston, Clinical geneticists' attitudes and practice towards testing for breast cancer susceptibility genes, J Med Genet 37 (2000), 157-160.
73. H.T. Lynch, C. Snyder; J.F. Lynch, P. Karatoprakli, A. Trowonou, K. Metcalfe, S.A. Narod and G. Gong, Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families, Cancer Genet Cytogenet 165 (2006), 91-97.
74. H.T. Lynch, S.J. Lemon, C. Durham, S.T. Tinley, C. Connolly, J.F. Lynch, J. Surdam, E. Orinion, S. Slominski-Caster, P. Watson, C. Lerman, P. Tonin, G. Lenoir, O. Serova and S. Narod, A descriptive study of BRCA1 testing and reactions to disclosure of testing results, Cancer 79 (1997), 2219-2228.
75. H.T. Lynch, T. Smyrk and J. Lynch, An update of HNPCC (Lynch Syndrome), Cancer Genet Cytogenet 93 (1997), 84-99.
76. H.T. Lynch, P. Watson, T.A. Conway, J.F. Lynch, S.M. Slominski-Caster, S.A. Narod, J. Feunteun, G. Lenoir, H.T. Lynch, P.Watson, T.A. Conway, J.F. Lynch, S.M. Slominski-Caster, S.A. Narod, J. Feunteun and G. Lenoir, DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study, Arch Intern Med 153 (1993), 1979-1987.
77. E. Matloff, H. Shappell, K. Brierley, B.A. Bernhardt, W. McKinnon and B.N. Peskin, What would you do? Specialists' pespectives on cancer genetic testing, prophylactic surgery, and insurance discrimination, J Clin Oncol 18 (2000), 2484-2492.
78. G. Matthijs, The European opposition against the BRCA gene patents, Familial Cancer 5 (2006), 95-102.
79. E.J. Meijers-Heijboer, L.C. Verhoog, C.T. Brekelmans, C. Seynaeve, M.M. Tilanus-Linthorst, A. Wagner, L. Dukel, P. Devilee, A.M. van den Ouweland, A.N. van Geel, J.G. Klijn, E.J. Meijers-Heijboer, L.C. Verhoog, C.T. Brekelmans, C. Seynaeve, M.M. Tilanus-Linthorst, A. Wagner, L. Dukel, P. Devilee, A.M. van den Ouweland, A.N. van Geel and J.G. Klijn, Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation, see comment, Lancet 355 (2000), 2015-2020.
80. H. Meijers-Heijboer, B. van Geel, W.L. van Putten, S.C. Henzen-Logmans, C. Seynaeve, M.B. Menke-Pluymers, C.C. Bartels, L.C. Verhoog, A.M. van den Ouweland, M.F. Niermeijer, C.T. Brekelmans, J.G. Klijn, H. Meijers-Heijboer, B. van Geel, W.L. van Putten, S.C. Henzen-Logmans, C. Seynaeve, M.B. Menke-Pluymers, C.C. Bartels, L.C. Verhoog, A.M. van den Ouweland, M.F. Niermeijer, C.T. Brekelmans and J.G. Klijn, Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation, see comment, N Engl J Med 345 (2001 , 159-164.
81. B. Meiser, Psychological impact of genetic testing for cancer susceptibility: An update of the literature, Psychooncology 14 (2005), 1060-1074.
82. B. Meiser, P. Butow, A. Barratt, G. Suthers, M. Smith, A. Colley, E. Thompson and K. Tucker, Attitudes to genetic testing for breast cancer susceptibility in women at increased risk of developing hereditary breast cancer, J Med Genet 37 (2000), 472-476.
83. B. Meiser, P. Butow, M. Friedlander, V. Schnieden, M. Gattas, J. Kirk, G. Suthers, E. Haan and K. Tucker, Intention to undergo prophylactic mastectomy in women at increased risk of developing hereditary breast cancer, J Clin Oncol 18 (2000), 2250-2257.
84. B. Meiser, M. Eisenbruch, K. Barlow, K. Tucker, Z. Steel and D. Goldstein, Cultural aspects of cancer genetics: Setting a research agenda, J Med Genet 38 (2001), 425-429.
85. B. Meiser and J. Halliday, What is the impact of genetic counseling in women at increased risk of developing hereditary breast cancer: A meta-analytic review, Soc Sci Med 54 (2002), 1463-1470.
86. K. Metcalfe, A. Liede, E. Hoodfar, A. Scott, W. Foulkes and S. Narod, An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling, J Med Genet 37 (2000), 866-874.
87. S. Michie, A. Allanson, D. Armstrong, J.Weinmann, M. Bobrow and T.M. Marteau, Objectives of genetic counselling: Differing views of purchasers, providers and users, J Public Health Med 20 (1998), 404-408.
88. S. Michie, J. Smith, J. Heaversedge and S. Read, Genetic counseling: Clinical geneticists' views, Journal of Genetic Counseling 8 (1999), 275-287.
89. Y. Murakami, H. Okamura, K. Sugano, T. Yoshida, K. Kazuma, T. Akechi and Y. Uchitomi, Psychological distress after disclosure of genetic testing results regarding hereditary non-polypsos colorectal carcinoma: A preliminary report, Cancer 101 (2004), 395-403.
90. National Institute for Clinical Excellence, Clinical guidelines for the classification and care of women at risk of familial breast cancer (Clinical Guidelines 14). Developed by National Collaborating Centre for Primary Care/University of Sheffield (www.nice.org.uk), London: National Institute for Clinical Excellence, May 2004.
91. Genetic/familial high-risk assessment: Breast and Ovarian, www.nccn.org.
92. NSW Health, Genetics Services in NSW, 1996-2000, Sydney: 2002.
93. S. Parthasarathy, The patent is political: The consequences of patenting the BRCA genes in Britain, Community Genetics 8 (2005), 235-242.
94. N. Peters, A. Rose and K. Armstrong, The association between race and attitudes about predictive genetic testing, Cancer Epidemiol Biomarkers Prev 13 (2004), 361-365.
95. E. Petersen, K. Milliron, K. Lewis, S. Goold and S. Merajver, Health insurance and discrimination concerns and BRCA1/2 testing in a clinical population, Cancer Epidemilogy, Biomarkers and Prevention 11 (2002), 79-87.
96. K. Phillips, J. MA, G. Lindeman, S. McLachlan, J. McKinley, P. Weideman, J. Hopper, M. Friedlander and k. Investigators., Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: A prospective study, Clin Genet 70 (2006), 198-206.
97. K.A. Phillips, E. Warner, W.E. Meschino, J. Hunter, M. Abdolell, G. Glendon, I. Andrulis and P.J. Goodwin, Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2, Clin Genet 57 (2000), 376-383.
98. T.R. Rebbeck, T. Friebel, H.T. Lynch, S.L. Neuhausen, L. van 't Veer, J.E. Garber, G.R. Evans, S.A. Narod, C. Isaacs, E. Matloff, M.B. Daly, O.I. Olopade, B.L. Weber, T.R. Rebbeck, T. Friebel, H.T. Lynch, S.L. Neuhausen, L. van 't Veer, J.E. Garber, G.R. Evans, S.A. Narod, C. Isaacs, E. Matloff, M.B. Daly, O.I. Olopade and B.L. Weber, Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group, see comment, J Clin Oncol 22 (2004), 1055-1062.
99. J.G. Reichelt, K. Heimdal, P. Moller and A.A. Dahl, BRCA1 testing with definitive results: A prospective study of psychological distress in a large clinic-based sample, Familial Cancer 3 (2004), 21-28.
100. M. Ropka, J. Wenzel, E. Phillips, M. Siadaty and J. Philbrick, Uptake rates for breast cancer genetic testing: A systematic review, Cancer Epidemiol Biomarkers Prev 15 (2006), 840-855.
101. L. Scheuer, N. Kauff, M. Robson, B. Kelly, R. Barakat, J. Satagopan, N. Ellis, M. Hensley, J. Boyd, P. Borgen, L. Norton and K. Offit, Outcome and preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers, J Clin Oncol 20 (2002), 1260-1268.
102. J. Schmidtke, B. Pabst and I. Nippert, DNA-based genetic testing is rising steeply in a national health care system with open access to services: A survey of genetic test use in Germany, 1996-2002, Genet Test 9 (2005), 80-84.
103. M. Schwartz, C. Hughes, J. Roth, D. Main, B. Peshkin, C. Isaacs, C. Kavanagh and C. Lerman, Spiritual faith and genetic testing decisions among high-risk breast cancer probands, Cancer Epidemiol Biomarkers Prev 272 (2000), 1885-1892.
104. M. Schwartz, C. Lerman, B. Brogan, B. Peshkin, C. Hughes Halbert, T. DeMarco, W. Lawrence et al., Impact of BRCA1/2 counseling and testing on newly diagnosed breast cancer patients, J Clin Oncol 22 (2004), 1823-1829.
105. M.D. Schwartz, B.N. Peshkin, C. Hughes, D. Main, C. Isaacs and C. Lerman, Impact of BRCA1/BRCA2 mutation testing on psychological distress in a clinic-based sample, J Clin Oncol 20 (2002), 514-520.
106. M.D. Schwartz, E. Kaufman, B.N. Peshkin, C. Isaacs, C. Hughes, T. DeMarco, C. Finch and C. Lerman, Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing, J Clin Oncol 21 (2003), 4034-4041.
107. C. Scott, D. Iorgulescu, H. Thorne, M. Henderson and K. Phillips, Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy, Clin Genet 64 (2003), 111.
108. K.R. Smith, J.A. West, R.T. Croyle and J.R. Botkin, Familial context of genetic testing for cancer susceptibility: Moderating effect of siblings' test result on psychological distress one to two weeks after BRCA1 mutation testing, Cancer Epidemiol Biomarkers Prev 8 (1999), 385-392.
109. M.E. Stefanek, Bilateral prophylactic mastectomy: Issues and concerns, J Natl Cancer Inst Monograph No. 17 (1995), 37-42.
110. T. Stermer, S. Hodgson, F. Kavalier, S. Watts and R. Jones, Patients' and professionals' opinions of services for people at an increased risk of colorectal cancer: An exploratory qualitative study, Familial Cancer 3 (2004), 49-53.
111. J.P. Struewing, C. Lerman, R.G. Kase, T.R. Giambarresi and M.A. Tucker, Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer, Cancer Epidemiol Biomarkers Prev 4 (1995), 169-173.
112. K.P. Tercyak, C. Lerman, B.N. Peshkin, C. Hughes, D. Main, C. Isaacs and M.D. Schwartz, Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk, Health Psychol 20 (2001), 217-222.
113. H.S. Thompson, H.B. Valdimarsdottir, L. Jandorf and W. Redd, Perceived disadvantages and concerns about abuses of genetic testing for cancer risk: Differences across African American, Latina and Caucasian women, Patient Education & Counseling 51 (2003), 217-227.
114. K. Tiller, B. Meiser, P. Butow, M. Clifton, B. Thewes, M. Friedlander and K. Tucker, Psychological impact of prophylactic oophorectomy in women at risk of developing ovarian cancer, Gynecol Oncol 86 (2002), 212-219.
115. U.S. Preventive Services Task Force, Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement, Annals of Internal Medicine 143 (2005), 355-361.
116. C. van Asperen, G. de Bock, F. van der Horst, H. de Konig and E. Rutgers, Screening for breast cancer on the basis of individual risk assessment for women eligible for the national screening program (in Dutch), Ned Tijdschr Geneeskd 145 (2001), 120-125.
117. C.J. Van Asperen, S. Van Dijk, M.W. Zoeteweij, D.R. Timmermans, G.H. De Bock, E.J. Meijers-Heijboer, M.F. Niermeijer, M.H. Breuning, J. Kievit, W. Otten, C.J. Van Asperen, S. Van Dijk, M.W. Zoeteweij, D.R.M. Timmermans, G.H. De Bock, E.J. Meijers-Heijboer, M.F. Niermeijer, M.H. Breuning, J. Kievit and W. Otten, What do women really want to know? Motives for attending familial breast cancer clinics, comment, J Med Genet 39 (2002), 410-414.
118. S. van Dijk, W. Otten, M.W. Zoeteweij, D.R. Timmermans, C.J. van Asperen, M.H. Breuning, R.A. Tollenaar and J. Kievit, Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment, Br J Cancer 88 (2003), 1675-1681.
119. S.T. van Dijk, D. R; Meijers-Heijboer, H; Tibben, A; van Asperen, C. J; Otten, W., Clinical characeristics affect the impact of an uninformatie DNA test result: The course of worry and distress experienced by women who apply for genetic testing for breast cancer, J Clin Oncol 24 (2006), 3672-3677.
120. I. van Oostrom, E. Meijers-Heijboer, H. Duivenvoorden, A. Brocker-Vriends, C. van Asperen, R. Sijmons, C. Seynaeve, A. van Gool, J. Klijn and A. Tibben, Family System Characteristics and Psychological Adjustment to Cancer Susceptibility Genetic Testing: A Prospective Study, Clin Genet 71 (2007), 35-42.
121. I. van Oostrom, H. Meijers-Heijboer, H. Duivenvoorden, A. Brocker-Vriends, C. van Asperen, R. Sijmons, C. Seynaeve, A. van Gool, J. Klijn and A. Tibben, Experience of Parental Cancer in Childhood Is a Risk Factor for Psychological Distress During Genetic Cancer Susceptibility Testing, Annals Oncology 17 (2006), 1090-1095.
122. I. van Oostrom, H. Meijers-Heijboer, L. Lodder, H. Duivenvoorden, A. van Gool, C. Seynaeve, C. van der Meer, J. Klijn, B. van Geel, C. Burger, J. Wladimiroff and A. Tibben, Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: A 5-year follow-up study, J Clin Oncol 21 (2003), 3867-3874.
123. M.S. van Roosmalen, P.F. Stalmeier, L.C. Verhoef, J.E. Hoekstra-Weebers, J.C. Oosterwijk, N. Hoogerbrugge, U. Moog, W.A. van Daal, M.S. van Roosmalen, P.F.M. Stalmeier, L.C.G. Verhoef, J.E.H.M. Hoekstra-Weebers, J.C. Oosterwijk, N. Hoogerbrugge, U. Moog and W.A.J. van Daal, Impact of BRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer, American Journal of Medical Genetics Part A 124 (2004), 346-355.
124. A. Vodermaier, Prophylaktische Chirurgie bei Brust-und Eierstockkrebsrisiko aus psychologischer Perspektive Prophylactic surgery in women at risk for breast and ovarian cancer from a psychological perspective, Dissertation, LMU Munich: Faculty of Psychology and Educational Sciences, 2005, http://edoc.ub.uni-muenchen.de/archive/00004248/.
125. S. Wainberg and J. Husted, Utilization of screening and preventive surgery among unaffected carriers of BRCA1 and BRCA2 gene
126. M. Watson, C. Foster, R. Eeles, D. Eccles, S. Ashley, R. Davidson, J. Mackay, P. Morrison, P. Hopwood and D. Evans, Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre cohort, Br J Cancer 91 (2004), 1787-1794.
127. M. Watson, V. Murday, B. Ponder, D. Averill and R. Eeles, Genetic testing in breast/ovarian cancer (BRCA1) families, Lancet 346 (1995), 583.
128. J. Weil, Multicultural education and genetic counseling, Clin Genet 59 (2001), 143-149.
129. D. Wonderling, P. Hopwood, A. Cull, F. Douglas, M. Watson, J. Burn and K. McPherson, A descriptive study of UK cancer genetic services: An emerging response to the new genetics, Br J Cancer 85 (2001), 166-170.
130. U. Worringen, Genetische Diagnostik bei familiärem Brust-und Eierstockkrebs: Risikowahrnehmung, Früherkennungsverhalten, Einstellungen und Untersuchungsintention Genetic testing for hereditary breast and ovarian cancer: Risk perception, prevention behavior, attitudes and intention to get tested, Dissertation, University of Freiburg: Faculty of Philosophy I, 2001, http://www.freidok.uni-freiburg.de/volltexte/435/.